The development of afluorescent LCK inhibitor that exhibits favourable solvatochromic properties upon binding the kinase is described. Fluorescent properties were realised through the inclusion of aprodan-derived fluorophore into the pharmacophore of an ATP-competitive kinase inhibitor. Fluorescence titration experiments demonstrate the solvatochromic properties of the inhibitor,inwhichdramatic increase in emission intensity and hypsochromic shift in emission maxima are clearly observed upon binding LCK. Microscopy experiments in cellular contexts together with flowc ytometry show that the fluorescence intensity of the inhibitor correlates with the LCK concentration. Furthermore,m ultiphoton microscopye xperiments demonstrate both the rapid cellular uptake of the inhibitor and that the two-photon cross section of the inhibitor is amenable for excitation at 700 nm.
Such characteristics allow the researcher to distinguish between bound and unbound molecules,g aining further insight into subcellular localisation and the underlying mechanisms of substrate activation or inhibition.
Thep rodan fluorophore ( Figure 1 ) has been highly utilised to probe biological systems due to its desirable spectroscopic properties,i ncluding high fluorescence quantum yield and molar absorption coefficient, pronounced solvatochromism, good photostability as well as al arge cross section for two-photon absorption (75 GM in EtOH). [2] To date,p rodan has seen extensive use as an environment-sensitive dye to probe the binding sites of proteins [3] and DNA, [4] as well as the structural and dynamic changes in cellular membrane properties. [5] Furthermore, prodan and its analogues (Supporting Information, Figure S1 ) have also demonstrated their utility as two-photon excitable fluorophores for in-depth live-tissue imaging [6] and the imaging of lipid membranes, [7] amyloid-b plaques, [8] and toxic cadmium deposits in cells. [9] Thea berrant regulation of kinase enzymes is associated with virtually all major disease areas and are therefore regarded as important drug targets. [10] Despite the advantages of fluorescence imaging in live cells,there are only ahandful of examples in which fluorescent kinase inhibitors have been employed as at ool to study kinase inhibition in ac ellular setting, [11] while even fewer have been utilised for in vivo imaging studies. [12] In light of this,w ed escribe herein the design, synthesis, and photophysical as well as the biological characterisation of small prodan-based ATP-competitive kinase inhibitors ( Figure 1 ). Theeffect of the conjugation of the linker between the fluorescent moiety and the heterocyclic core (i.e.a lkane vs.alkyne) as well as the importance of the carbonyl group in the prodan fluorophore was of particular interest.
Thep yrazolo [3,4-d] pyrimidine heterocycle serves as an important scaffold in an umber of ATP-competitive kinase inhibitors (Supporting Information, Figure S2 ). [13] We therefore anticipated that the introduction of the fluorescent moiety at the 3-position of the heterocycle would readily be accommodated in the active site,astheprodan moiety would extend out into the hydrophobic back pocket. As the fluorescent moiety would experience am uch less polar environment compared to aqueous solution, af luorophore that displays pronounced solvatochromism could therefore report, by photonic means,t hat binding to the kinase has occurred.
Theprodan-derivatives were synthesised and their photophysical properties thoroughly evaluated (see the Supporting Information for synthetic details). Absorption and emission spectra of prodan and compounds 1-6 were recorded in solvent systems of varying polarity (Table 1a nd Supporting Information, Tables S1-S2 for additional spectroscopic prop-erties). Both prodan and 1 ( Figure 1 ) were chosen to represent the parent fluorophores.P rodan as well as 2 and 3 display ar ed-shifted absorption in aqueous solution compared to aprotic solvents,while the opposite effect is observed for 5 and 6.T he absorption maximum of 4 shows very little dependencyo nt he solvent polarity (Table 1a nd Supporting Information, Figure S7 ). In comparison to prodan and the other derivatives,t he absorption maximum of 2 is significantly red-shifted, reflecting the most extended conjugated system (Table 1a nd Supporting Information, Figure S5 ). Furthermore,a ll compounds with an extended conjugated system (2, 4,a nd 5)e xhibit ah igher molar absorption coefficient compared to prodan (Table 1) . As for the fluorescence properties,a ll compounds display positive solvatochromism (red-shifted fluorescence with increasing polarity). It is encouraging to note that the pronounced solvatochromism is preserved also for the compounds that do not contain the carbonyl moiety from the prodan motif (1 and 4-6; Table 1a nd Supporting Information, Figures S4 and S7-S9). Compounds 2, 5,a nd 6 are the weakest emitters in aqueous solution (F F < 0.01), while 3 and 4 display moderately stronger fluorescence (F F = 0.06 and 0.03, respectively, Table 1 ). However, for all derivatives in less polar organic solvents (toluene and acetonitrile), the fluorescence quantum yields are significantly higher,along with apronounced blueshift due to the strong solvatochromism of these fluorescent entities.Inaqueous solution, it is clear that 2-6 display weaker fluorescence compared to the parent fluorophores prodan and 1.A lthough no redox-data are available,avery likely explanation is photoinduced electron transfer quenching, known to be accelerated in polar media. [14] Thesignificant decrease in fluorescence quantum yields in aqueous solution is also reflected in the fluorescence lifetimes.W ith the exception of 1,all derivatives display shorter lifetimes in aqueous solution compared to toluene and acetonitrile (Table 1a nd Supporting Information, Table S2 ). These results support the notion that the internal charge transfer state of prodan and 2-6 undergo ar apid nonradiative decay in aqueous solution.
Due to their favourable fluorescent properties in aqueous solution, 3 and 4 were evaluated for their ability to inhibit protein kinases.I ne fforts to gauge both the efficacy and selectivity of compounds 3 and 4,i nitial testing consisted of ak inome screen against ap anel of 65 kinases (at 1 mm, Supporting Information, Table S3 ). This panel was selected to reflect that of the human kinome and included examples from each of the major kinase subfamilies.W hilst the nonconjugated derivative 3 exhibited little to no kinase inhibition (> 60 %r emaining kinase activity was observed for all 65 kinases tested), the conjugated derivative 4 exhibited strong inhibitory properties towards Aurora-A, Blk, and LCK ( 15 %remaining kinase activity). No inhibitory activity against 52 kinases (> 76 %r emaining kinase activity) was observed. Cell-free IC 50 assays were then performed to further assess the inhibitory properties of 4 against Aurora-A, Blk, and LCK (Supporting Information, Table S4 ). Compound 4 was found to exhibit moderate activity against Aurora-A and Blk with IC 50 values of 222 nm and 554 nm,r espectively,w hile an IC 50 of 124 nm was obtained for LCK. In light of these results, 4 has emerged as an interesting molecular tool in which fluorescence can be employed to study LCK inhibition.
Given the strong solvatochromic properties of 4 and the hydrophobic active site of kinases,i tw as envisioned that binding of the prodan-based LCK inhibitor 4 may result in the onset of intense blue-shifted emission. Fluorescence titration experiments were undertaken to investigate this notion, in which aliquots of as olution of 4 were added to as olution of LCK (1 mm). Over the course of the experiment, changes in both the emission maximum and intensity were monitored and subsequently plotted to afford the corresponding binding isotherm (Figure 2a nd Supporting Information, Figure S11 ).
Ad ramatic increase in emission intensity as well as ab lueshift was indeed observed upon binding LCK (at 1:1 4:LCK, emission intensity is 400-fold higher than for unbound 4). After the addition of 1.0 equivalent of inhibitor,t he curve plateaued. This strongly suggests a1:1 binding stoichiometry to the active site.M oreover,t he linear nature of the binding isotherm below this inflection point shows that the binding is near quantitative at all concentrations and infers that binding is too strong to allow for the determination of the binding constant. [15] Upon increasing the amount of inhibitor, asecond binding regime was observed (Supporting Information, Figure S11 ), likely to be explained by nonspecific binding.D isplacement experiments with the non-fluorescent ATP-competitive LCK inhibitor TC-S7003 (IC 50 = 7nm) [16] strongly support the aforementioned notion. Upon titrating TC-S7003 (0-2.0 equiv) to a1:1 complex of 4:LCK, adramatic decrease in emission from 4 was observed ( Figure 2C) , implying that 4 binds almost exclusively to the ATP-binding site of LCK at concentrations lower than 1equivalent.
Fluorescence titration experiments using JAK2 (a kinase in which 4 did not exhibit kinase activity for in the kinome screen) in place of LCK were also performed. Upon monitoring changes in the emission maximum and intensity, the resulting binding isotherm shows no signs of strong specific binding at concentrations below 1 mm (Supporting Information, Figure S13 ). Furthermore,s ignificant increases in fluorescent intensity were not observed upon increasing concentration of 4 (0-30 equiv).
Fluorescence microscopy was used to investigate the properties of 4 in acellular context. LCK-positive Jurkat cells were incubated with 4 at concentrations of 5nm-5 mm for 15 minutes (Supporting Information, Figure S16 ). Strong intracellular emission was observed at 0.5 and 5 mm,d emonstrating rapid cellular uptake ( Figure 3B,C) . Theo bserved cellular accumulation of 4 is in agreement with the reported LCK localisation (cytosolic side of the plasma membrane, intracellular vesicles,a nd the Golgi apparatus). [17] In as eparate experiment, Jurkat cells incubated with 4 at 5 mm were costained with an LCK-specific antibody conjugated with Alexa 647 (anti-LCK-AF647). Partial co-localisation was clearly observed in intracellular vesicles,s uggesting that the observed emission intensities from 4 correlate with the intracellular LCK concentration (Figure 3D,F) . Furthermore,L CK-negative A498 cells transfected with ap lasmid encoding wild-type untagged LCK were treated with 4 (0.5 mm), co-stained with anti-LCK-AF647, and analysed using microscopy ( Figure 4A-C) . In comparison to the population of non-transfected cells (see Figure 4A ,region indicated by the white box), the transfected cells exhibited al arge degree of co-localisation of 4 with anti-LCK-AF647, again supporting ahigh affinity of 4 for LCK.
To quantify the effect of an increased LCK concentration on the emission intensity of 4,t he LCK deficient cell line K562 (well-suited for flow cytometry measurements) was electroporated with the aforementioned plasmid encoding LCK. While the efficiency of the electroporation was low (approximately 4%), the overexpression of LCK resulted in as ignificant increase (40 %) in fluorescence intensity from 4 compared to the non-transfected K562 cells.The corresponding increase in the fluorescence observed from anti-LCK-AF647 (around af actor of 500) is much more pronounced compared to 4.T his is consistent with the microscopy results in which fluorescence from unspecific binding of 4 is seen ( Figure 4B,region indicated by white box) .
In efforts to demonstrate the applicability of 4 to multiphoton fluorescence imaging,two-photon microscopy (TPM) experiments were undertaken using the human lung cancer cell line,H TB-177. Cells were treated with as olution of 4 at concentrations of 0.1-10 mm for 5minutes and images were acquired following excitation at 700 nm. At concentrations of 0.5-10 mm strong intracellular emission was observed (Supporting Information, Figure S19 ). These results clearly demonstrate that 4 exhibits af avourable cross section for TPM experiments.
To conclude,asmall ATP-competitive LCK inhibitor (IC 50 = 124 nm)w ith innate fluorescent properties has been realised through the integration of ap rodan-derived fluorophore into the pharmacophore of the kinase inhibitor. Fluorescence titration experiments with LCK demonstrate adramatic increase in emission intensity as well as ablue-shift of the emission maximum upon binding to LCK. Furthermore,anincrease in fluorescence intensity of 4 correlates with an increase in LCK concentration, as observed in microscopy and flow cytometry experiments,w hile multiphoton imaging experiments in live cells demonstrated that compound 4 exhibits af avourable cross section for TPM experiments. Thep rodan-derived LCK inhibitor could serve as av aluable molecular tool for real-time intracellular studies of LCK signalling,with its unique solvatochromic properties allowing the user to distinguish between bound and unbound molecules in ac ellular setting. 
